



Provisional Programme

(contents subject to change)

RAI Amsterdam, the Netherlands

9 to 11 December 2026

(on-demand access available until 3 March 2027)

Wednesday 9 December

Session 1 Joint Opening Session	
08:30 – 08:35	Welcome – A Al-Chalabi (UK) and B Dickie (UK)
08:35 – 08:45	Welcome from Stichting ALS Nederland/ALS Centrum Nederland/ALS Patiënten Vereniging – TBC (Netherlands)
08:45 – 09:25	C1 <i>Stephen Hawking Memorial Lecture</i>: Toward therapy for ALS: SOD1 and beyond – R Brown (USA)
09:25 – 09:30	Drs. Ayeez and Shelena Lalji and Family ALS Endowed Award for Innovative Healing
09:30 – 09:40	International Alliance Forbes Norris Award
09:40 – 10:00	IPG Award and winner's research presentation

10:00 – 10:30 Coffee

Session 2A Clinical Trials	Session 2B Genetics
10:30 – 10:45 C2 Safety and efficacy of lithium carbonate for patients with ALS homozygous for the C-allele at SNP rs12608932 in UNC13A: Results for a Phase 3 randomised double-blind, placebo-controlled trial S Willemse (Netherlands)	10:30 – 11:00 C10 Motor neuron disease / amyotrophic lateral sclerosis in India: Emphasis on genetic landscape A Nalini (India)

10:45 – 11:00 C3 Efficacy and tolerability of β-hydroxybutyrate in patients with ALS (KETO-ALS): A randomised, placebo-controlled, double-blind study J Dorst (Germany)	11:00 – 11:15 C11 Genotype-phenotype correlations in over 500 patients with TARDBP-related ALS/FTD: Results from a new research cohort and comprehensive literature review M Harms (USA)
11:00 – 11:15 C4 VHB937 efficacy and safety in people with ALS: Primary results from the double-blind, randomized, placebo-controlled phase 2 ASTRALS trial L van den Berg (Netherlands)	11:15 – 11:30 C12 Oligogenic action of pleiotropic neurodegenerative repeat expansions in ALS G Venslovaite (Ireland)
11:15 – 11:30 C5 Extended survival results from DAZALS: A phase 2 randomized controlled trial of Dazucorilant, a selective glucocorticoid receptor modulator, in ALS L van den Berg (Netherlands)	11:30 – 11:45 C13 Genetic variants related to a familial C9orf72 penetrance score in FTD and ALS N Deghani (USA)
11:30 – 11:45 C6 Healey ALS MyMatch: Digoxin in ACACIA trial and rapid drug purposing in ALS S Babu (USA)	11:45 – 12:00 C14 Retrotransposons: A new era for novel sources of genetic risk for neurodegenerative disorders B Middlehurst (UK)
11:45 – 12:00 C7 Metformin shows favourable safety and reduces RAN proteins, markers of neurodegeneration and neuroinflammation in C9orf72 ALS patients in a Phase 2 open-label clinical trial L Ranum (USA)	12:00 – 12:15 C15 Hidden viral signatures in ALS: Locus-specific transcriptomics reveals dysregulated human endogenous retrovirus loci N Sai (Australia)
12:00 – 12:15 C8 FUSION, a phase 1-3 clinical trial of ulefnersen in people with ALS with fused in sarcoma variants (FUS-ALS): trial design and baseline characteristics N Schneider (USA)	12:15 – 12:30 C16 Sex-specific DNA methylation differences in ALS Y Kim (UK)

12:15 – 12:30 C9 Results from ANQUR: a Phase 1/2b MAD and Dose-Range Finding Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of QRL- 201, A <i>STMN2</i> Targeting Splice-Switching ASO for the Treatment of Sporadic and C9orf72 ALS T Gray (USA)	
---	--

12:30 – 14:00 Lunch

Session 3A Proteostasis	Session 3B C22 Transitioning from Phase 2 to Phase 3 in ALS Clinical Trials: Balancing Signals of Biological Activity, Clinical Efficacy, and Uncertainty	Session 3C Neuroimaging
14:00 – 14:30 C17 Physiological and pathological roles of phase separation D Dormann (Germany)	14:00 – 14:15 R van Eijk (Netherlands)	14:00 – 14:30 C23 Imaging prodromal ALS H-J Westeneng (Netherlands)
14:30 – 14:45 C18 Cryo-EM atomic pathology of ALS and associated diseases A Giblin (UK)	14:15 – 14:30 S Paganoni (USA)	14:30 – 14:45 C24 C9orf72 specific hypothalamic atrophy precedes ALS-FTD phenoconversion N Schweitzer (USA)
14:45 – 15:00 C19 Distinct routes to abnormal TDP-43 oligomerisation in C9orf72 and sporadic ALS T Shelkovernikova (UK)	14:30 – 14:45 M Barlow (UK)	14:45 – 15:00 C25 Functional connectivity outperforms regional metrics as a trial-ready resting state fMRI biomarker in ALS: A multicenter longitudinal validation P Parnianpour (Canada)
15:00 – 15:15 C20 Cytoplasmic TDP-43 alters neuronal lysosome localisation, transport, cargoes and degradation capacity in ALS S Keating (Australia)	14:45 – 15:00 T Cochrane (USA)	15:00 – 15:15 C26 Estimated monthly rate of spinal cord atrophy (EMSA): A spinal cord single-scan imaging marker for survival prediction in ALS M Wendebourg (Switzerland)

15:15 – 15:30 C21 Cystatin C and Bunina bodies as novel drivers of TDP-43 proteinopathy in ALS S Granger (UK)	15:00 – 15:30 Q&A/Panel Discussion	15:15 – 15:30 C27 Combined [18F]SynVesT-1 PET imaging and CSF levels identify SV2A as a multimodal biomarker for synaptic dysfunction in ALS F Hobin (Belgium)
---	---	--

15:30 – 16:00 Coffee

Session 4A Glia	Session 4B ALS-FTD	Session 4C Optimising Care
16:00 – 16:15 C28 Astrocyte dysfunction distinguishes monozygotic twin C9orf72 expansion carriers discordant for ALS A Shaw (UK)	16:00 – 16:40 C34 Will that be three lumps or one? The conundrum of defining ALS, ALS-FTSD and FTD as a single entity J Robertson (Canada), M Strong (Canada)	16:00 – 16:15 C36 The Rapid Access ALS Clinic model: A step towards addressing ALS diagnostic delay K Gwathmay (USA)
16:15 – 16:30 C29 Glial hnRNP network dysregulation reveals distinct RNA processing signatures across sporadic and C9orf72-associated FTLD-TDP A Gatt (UK)	16:40 – 17:10 C35 The FTD/ALS proteins Annexin A11 and CHMP2B act sequentially in plasma membrane repair A Isaacs (UK)	16:15 – 16:30 C37 Decoding healthcare complexity in ALS: A multidimensional analysis of resource allocation and predictive drivers at hospital admission F Cerri (Italy)
16:30 – 16:45 C30 ALS-FTD-linked CCNFS621G drives increased hippocampal astrocyte ramification and mitochondrial dysfunction, and impairs motor neuron excitability L Ooi (Australia)	17:10 – 17:30 Q&A/Panel Discussion	16:30 – 16:45 C38 Health outcomes research in ALS: Social determinants of health enrich real-world data M Galvin (Ireland)

16:45 – 17:00 C31 Disrupted RNA binding protein network in oligodendrocytes rewires neuronal epigenome and leads to cognitive impairment in ALS L Dupuis (France)		16:45 – 17:00 C39 Cost-effectiveness of multidisciplinary care in ALS: Survival gains at what cost? S Hundai (Canada)
17:00 – 17:15 C32 An activation continuum governing oligodendrocyte vulnerability in the human central nervous system M Georgopolou (Belgium)		17:00 – 17:15 C40 Complex relationships: People living with MND and family perspectives of homecare E Wilson (UK)
17:15 – 17:30 C33 Oligodendrocyte dysfunction as an active contributor to ALS/MND: A three phase disease trajectory driven by TDP-43 mislocalisation T Atienzar (UK)		17:15 – 17:30 C41 Momentary perceptions of care for ALS caregivers: assessing day-to-day well-being in young carers M Kavanaugh (USA)

17:45 – 19:30 Poster Session A

Thursday 10 December

Session 5A Organoids	Session 5A Metabolism and Nutrition	Session 5C Clinical Electrophysiology
08:30 – 09:00 C42 Cystic fibrosis organoids for precision medicine: Lessons for other diseases J Beekman (Netherlands)	08:30 – 09:00 C46 Metabolic changes in ALS: Linking metabolism, disease progression and therapeutic targets S Ngo (Australia)	08:30 – 08:45 C51 Divergent cortical drive predicts survival in ALS M Conwill (UK)
09:00 – 09:30 C43 Neural organoids as human models for investigating ALS pathogenesis and therapeutic discovery J Pasterkamp (Netherlands)	09:00 – 09:15 C47 Characterizing energy metabolism among people with ALS and pathogenic gene carriers I Lee (USA)	08:45 – 09:00 C52 The ALS Methodology Natural History Study: A longitudinal head-to-head comparison of electrophysiological and clinical outcome measures C Neuwirth (Switzerland)
09:30 – 09:45 C44 A human corticospinal organoid-slice connectoid model for early mechanistic and therapeutic discoveries in ALS A Lakatos (UK)	09:15 – 09:30 C48 Resting blood lactate predicts survival and weight loss in ALS: An international exploratory-validation study R Nakamura (Australia)	09:00 – 09:15 C53 Advancing MScan-MUNE as an endpoint for clinical trials in ALS: Recommendations to minimize floor effects in phase 2 trials D Garcia (Netherlands)
09:45 – 10:00 C45 Deciphering the epigenetic and transcriptomic landscape of traumatic injury in asymptomatic C9orf72 mutation carriers using hiPSC-derived organoids K Baskar (Italy)	09:30 – 09:45 C49 A lean phenotype in C9orf72 repeat-expansion carriers does not explain ALS penetrance: an analysis of data from the UK Biobank A Strange (UK)	09:15 – 09:30 C54 Fasciculation frequency behaviour and ALS progression: A clinical-neurophysiological study M Santos (Portugal)
	09:45 – 10:00 C50 Characterising microbial markers predictive for ALS onset and progression C Jaing (USA)	09:30 – 09:45 C55 Longitudinal decline in beta-band EEG power tracks ALS progression S Dukic (Netherlands)

		09.45 – 10.00 C56 Disease-specific aperiodic EEG exponent signatures reflect distinct cortical excitation-inhibition imbalance across neurodegeneration: ALS as a uniquely identifiable pattern K-D Tran (Singapore)
--	--	--

10:00 – 10:30 Coffee

Session 6A Preclinical Therapeutic Strategies	Session 6B ALS/MND Heterogeneity	Session 6C Epidemiology
10:30 – 10:45 C57 A multi-target combination approach to novel therapeutic strategy in C9orf72-ALS M Cattaneo (Italy)	10:30 – 11:00 C65 Why is deep phenotyping important? T Meyer (Germany)	10:30 – 11:00 C72 How can we identify and quantify the environmental component of ALS risk? F Fang (Sweden)
10:45 – 11:00 C58 Novel brain-penetrating peptides restore autophagy and confer therapeutic benefit in ALS A Amin (Australia)	11:00 – 11:15 C66 What do ALS motor phenotypes measure? A population-based decomposition of the OPM classification's prognostic dimensions A Chio (Italy)	11:00 – 11:15 C73 Exposome-wide association study (ExWAS) in ALS I van Wijk (Netherlands)
11:00 – 11:15 C59 ACE-2223, a first-in-class oral small molecule for sporadic ALS, treats both gain- and loss-of-function TDP-43 pathology, extends survival and decreases NfL in mice K Planey (USA)	11:15 – 11:30 C67 Stratification and prognosis prediction for patients with ALS: Development and validation of a phenotyping strategy J Zhang (China)	11:15 – 11:30 C74 Use of muscle relaxants is associated with higher incidence of ALS: A cohort study from the UK Biobank and systematic review J-H Deng (China)

11:15 – 11:30 C60 SYF2-targeting antisense oligonucleotides correct TDP-43 pathology and rescue motor neurons: <i>In vivo</i> proof-of-concept and early safety for a novel ASO program in ALS/FTD W-H Chang (USA)	11:30 – 11:45 C68 Identifying phenotypic subgroups with distinct prognostic profiles in early-stage ALS using multidimensional clinical features: Results from a Chinese cohort Y Tan (China)	11:30 – 11:45 C75 Statin use and risk of ALS among U.S. military veterans: A large nested case-control study M Weisskopf (USA)
11:30 – 11:45 C61 Splice-correcting KCNQ2 and UNC13A therapies rescue paradoxical hyperexcitability and synaptic failure in TDP-43 ALS/FTD P Harley (UK)	11:45 – 12:00 C69 Muscle proteins in plasma associates with distinct phenotypes in ALS L Azizi (Sweden)	11:45 – 12:00 C76 The risk of ALS in a large cohort of male UK former professional footballers E Pupillo (UK)
11:45 – 12:00 C62 ENGRAILED-1 restores motor neuron survival and function in ALS models: Evidence for a homeoprotein signaling deficit in disease A Prochiantz (France)	12:00 – 12:15 C70 Neurobiological basis of bulbar involvement in ALS phenotypic heterogeneity S Marcuzzo (Italy)	12:00 – 12:15 C77 Founder-related genetic structure shapes geographic variation in ALS mortality in Finland H Hokkanen (Finland)
12:00 – 12:15 C63 Systemic administration of a cell-internalizing CYTOPE® targeting pTDP-43 reduces CNS intraneuronal pathology in a mouse model of TDP-43 proteinopathy S Tam (USA)	12:15 – 12:30 C71 Correlating clinical heterogeneity with cellular phenotypes in an expanded cohort of C9orf72-ALS induced neural progenitor cells (iNPCs) A Shaw (UK)	12:15 – 12:30 C78 Examining the age-incidence curves of ALS across European registers R McFarlane (Ireland)
12:15 – 12:30 C64 AAV-mediated gene augmentation therapy for NEK1-ALS K Meijboom (USA)		

12:30 – 14:00 Lunch

Session 7A RNA Dysregulation	Session 7B Presymptomatic and Early Disease Markers	Session 7C Assistive Technology
14:00 – 14:15 C79 Modelling RNA-binding protein loss-of-function in human iPSC neurons and assembloids to identify MND-relevant RNA processing signatures and targetable splice events M White (UK)	14:00 – 14:15 C85 From compensation to collapse: Elucidating the biology of pre-symptomatic ALS M Benatar (USA)	14:00 – 14:15 C91 Rewriting the future of disability B Muller (Netherlands)
14:15 – 14:30 C80 ALS4 associated senataxin mutation disrupts R-loop dependent local and distal transcriptional regulation in human motor neurons J Bussgang (USA)	14:15 – 14:30 C86 Associations between pre-diagnosis plasma neurofilament light polypeptide and ALS risk in the Danish EPIC cohort M Weisskopf (USA)	14:15 – 14:30 C92 Implantable BCI devices for at-home use: Challenges and impact M Vanstensteel (Netherlands)
14:30 – 14:45 C81 Unravelling the relationship between tau dysregulation and RNA-binding protein dysfunction in C9orf72- ALS T Petrozziello (USA)	14:30 – 14:45 C87 Spatiotemporal transcriptomics reveals early dysregulation in pre-symptomatic ALS skin H Spence (UK)	14:30 – 14:45 C93 Ultra-fast, non-invasive brain-computer interfaces for real-time control R Muresan (Romania)
14:45 – 15:00 C82 ALS causative gene ARPP21 drives TDP-43 proteinopathy and assembles into dynamic RNA granules A Aabdien (UK)	14:45 – 15:00 C88 MYL1 but not NfL is changed in CSF of presymptomatic ALS mutation carriers B Muqaku (Germany)	14:45 – 15:00 C94 Innovation to unlock creative expression. Exploring a new form of accessible, scalable, non-invasive brain-computer interface A Knight (Netherlands/Japan)
15:00 – 15:15 C83 A natural antisense lncRNA at the TBK1 locus defines a novel regulatory layer and potential therapeutic target in TBK1-ALS H Kinsella (Spain)	15:00 – 15:15 C89 Evaluating the viability of serum chitotriosidase as a minimally invasive diagnostic biomarker for early stage sporadic ALS S Narasappa (India)	15:00 – 15:30 Q&A/Panel Discussion

15:15 – 15:30 C84 TDP-43 dysfunction induces cryptic circular RNAs in ALS/FTD F Pellegrini (UK)	15:15 – 15:30 C90 A two-step blood neurofilament algorithm for biomarker-supported diagnosis of ALS J Dubin (Belgium)	
---	---	--

15:30 – 16:00 Coffee

Session 8A Immunity and Neuroinflammation	Session 8B Primary Lateral Sclerosis and Upper Motor Neuron Degeneration	Session 8C Respiratory Management
16:00 – 16:15 C95 Immune stimulation exacerbates cell autonomous microglial dysfunction in a stem cell model of TBK1-associated ALS-FTD U Chughtai (UK)	16:00 – 16:30 C101 From genes to therapies for the hereditary spastic paraplegias C Blackstone (USA)	16:00 – 16:30 C106 Assessment and management of upper airway dysfunction during respiratory therapies in ALS T Andersen (Norway)
16:15 – 16:30 C96 Progressive microglial and synaptic dysfunction in a novel mouse model of TBK1-associated frontotemporal dementia V Gerbino (Italy)	16:30 – 16:45 C102 Rate of disease progression, diagnostic change and biomarkers in Primary Lateral Sclerosis: 2-year follow up of the PLS Natural History Study cohort I Lee (USA)	16:30 – 16:45 C107 A data-driven respiratory reserve index predicts survival after NIV initiation in ALS F Cerri (Italy)
16:30 – 16:45 C97 A novel human motor neuron-microglia co-culture model identifies candidate neuroimmune responses to neuronal TDP-43 pathology L Nikel (UK)	16:45 – 17:00 C103 Diagnostic revision from PLS to ALS: A cohort study E de Boer (Netherlands)	16:45 – 17:00 C108 Point of care diaphragm ultrasound as a novel predictor of respiratory dysfunction in ALS: A prospective, longitudinal study D Ta (Canada)

16:45 – 17:00 C98 Microglia-sufficient spinal organoids effectively model ALS and elucidate neuro-immune crosstalk S Liu (Singapore)	17:00 – 17:15 C104 Metabolomic analysis of serum and plasma samples isolated from ALS and PLS patients begins to reveal key metabolite signatures for upper motor neuron vulnerability in MNDs H Ozdinler (USA)	17:00 – 17:15 C109 A longitudinal, mixed methods, real world evaluation of the implementation of remote monitoring of respiratory function to support clinical care in ALS L Musson (UK)
17:00 – 17:15 C99 Lower and upper motor neuron clinicopathology driven by nerve injury and neuroinflammation are viable therapeutic targets in ALS J Loeb (USA)	17:15 – 17:30 C105 Cervical spinal cord MRI and lateral column pallor reflect upper motor neuron burden across the PLS spectrum, independently of disease duration T Shaw (Australia)	17:15 – 17:30 C110 Effects of combined lung volume recruitment and expiratory strength training on pulmonary and cough function in people living with ALS L Gray (USA)
17:15 – 17:30 C100 IFN-1 signalling disrupts neuron-glia lipid metabolic coupling in MND C Low (Australia)	17:30 – 17:40 Presentation: <i>The Thurza Campbell Award for Basic Science Innovation in PLS; The Marren Family Award for Clinical Innovation in PLS</i>	

17:45 – 19:30 Poster Session B

Friday 11 December

Session 9A Cell Heterogeneity and Profiling	Session 9B Harnessing Technological Innovation
08:30 – 08:45 C111 Molecular subtypes in ALS: How the diversity of disease mechanisms could inform precision medicine approaches in clinical trials P Lingor (Germany)	08:30 – 08:45 C117 MND Alert: An electronic decision-support tool to support primary care practitioners with earlier detection and diagnosis of MND C Gates (UK)
08:45 – 09:00 C112 Altered age-dependent somatic mutational trajectories in ALS motor cortex neurons Li Liu (Netherlands)	08:45 – 09:00 C118 Designing and developing an intelligent chatbot to enhance personal insights related to Quality of Life based on the ALS/MND Personal Needs Matrix J Chudge (UK)
09:00 – 09:15 C113 Molecular correlates of TDP-43 pathology in human motor neurons revealed by spatial transcriptomics R De Souza (UK)	09:00 – 09:15 C119 Using digital services to support care pathways in MND: A mixed-methods process evaluation and economic analysis L Knox (UK)
09:15 – 09:30 C114 Spatial transcriptomic profiling reveals stage-dependent molecular responses to TDP-43 pathology in C9orf72-associated ALS J Gregory (UK)	09:15 – 09:30 C120 Impact of hybrid assistive limb on gait ability and quality of life in patients with ALS O Kano (Japan)
09:30 – 09:45 C115 Splitformer -V2 predicts multi-tissue RNA splicing and nominates ALS-associated splice-altering variants M Zhang (China)	09:30 – 09:45 C121 User expectations and experiences with eye-control glasses for complex power wheelchairs in people with ALS: A multicentre observational study R Schiemann (Germany)
09:45 – 10:00 C116 Subcellular transcriptomic signatures of C9orf72 and TARDBP mutations in hiPSC-derived motor neurons G Akbalik (USA)	09:45 – 10:00 C122 BCI-Augmented AAC in the home: A 3-5 month adaptive feasibility study of an EEG-enhanced Vision Pro system for Users with Motor and Speech Disabilities C Ullrich (USA)

10:00 – 10:30 Coffee

Session 10A Cell Biology and Pathology	Session 10B Cognitive and Behavioural Change	Session 10C Biomarkers
10:30 – 10:45 C123 AI-based identification of TDP-43 molecular and clinical subgroups in ALS/FTD by population iPS and large-scale human autopsy analytics J Rothstein (USA)	10:30 – 10:45 C131 Cognitive/behavioural impairment definition in ALS: An international survey on current methodologies and consensus criteria P Ferraro (Italy)	10:30 – 11:00 C139 Lipids in ALS: Driver, modifier or bystander? A Thompson (UK)
10:45 – 11:00 C124 A high-affinity peptide nucleic acid aptamer enables cross-platform detection of TDP-43 from cells to biofluids J Gregory (UK)	10:45 – 11:00 C132 Cognition, behaviour, and mood in an Indian ALS cohort: A cross-sectional observational study using multiple screening instruments and clinical correlates M Keerthipriya (India)	11:00 – 11:15 C140 Whole blood RNA-seq identifies diagnostic and prognostic signatures and therapeutic candidates for ALS Y Zhao (USA)
11:00 – 11:15 C125 Network synchrony disrupted upon TDP-43 loss is rescued by antisense oligonucleotides which prevent UNC13A cryptic exon inclusion E Ryadnov (UK)	11:00 – 11:15 C133 Optimized classification of cross-sectional and longitudinal cognitive screening in ALS F Hiemstra (Netherlands)	11:15 – 11:30 C141 ERACE (Emory Rapid Access Clinical Evaluation) 10-protein model predicts ALS from plasma with high accuracy E Thomas (USA)
11:15 – 11:30 C126 Age and ALS-dependent RANBP17 decline unlocks a TDP-43 vicious cycle G Haim (Israel)	11:15 – 11:30 C134 Behavioural reserve in ALS: Premorbid, socio-educational and biological determinants of behavioural impairment A Calvo (Italy)	11:30 – 11:45 C142 Identification of plasma and CSF biomarkers to predict ALS disease progression L Fichter (France)
11:30 – 11:45 C127 Shared and disease-specific alterations of nucleocytoplasmic transport in physiological aging and ALS A Juers (Germany)	11:30 – 11:45 C135 Identifying mild cognitive impairment in presymptomatic ALS: ECAS vs comprehensive assessment C McHutchinson (UK)	11:45 – 12:00 C143 Plasma and CSF prognostic biomarkers to predict ALS disease progression J Berry (USA)

11:45 – 12:00 C128 Investigating SRSF1-interfering gene therapy for treatment of sporadic ALS M Myszczyńska (UK)	11:45 – 12:00 C136 Cognition and behaviour in ALS (CABIA): Digital tools for early detection R Convery (UK)	12:00 – 12:15 C144 Proteomic convergence across blood and brain tissues in ALS R Tan (Australia)
12:00 – 12:15 C129 ARPP21 defines a TDP-43-independent aggregation pathway in ALS D Campos-Melo (Canada)	12:00 – 12:15 C137 CognoMND: Development and evaluation of a remote speech-analysis platform for automated cognitive screening in ALS L Ing (UK)	12:15 – 12:30 C145 Exploring TDP-43 - related fluid biomarkers as indicators of ALS progression: A 12-month longitudinal study M Chatterjee (Netherlands)
12:15 – 12:30 C130 FUS misfolding extends beyond FUS-ALS and increases with age across multiple ALS subtypes F Waldron (UK)	12:15 – 12:30 C138 The FTD Toolkit: A co-designed psychoeducational intervention for carers and healthcare professionals navigating the FTD-MND spectrum A Trucco (UK)	

12:30 – 13:30 Lunch

Session 11 Joint Closing Session	
13:30 – 13:35	Invitation to Dublin 2027
13:35 – 13:45	Poster Prizes
13:45 – 13:55	C146 The Global MND Research Roundtable – B Sheean (Australia)
13:55 – 14:30	Review of the Year – J Veldink (Netherlands)
14:30 – 14:40	Sean M Healey International Prize for Innovation in ALS
14:40 – 15.10	C147 Understanding heterogeneity in ALS: From Artificial Intelligence to Precision Therapeutics – C Yeo (Singapore)
15.10 – 15.20	Late breaking news